Zealand Pharma AS
Company Profile
Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNKT: +45 88773600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
544
Stocks News & Analysis
stocks
Undervalued wide moat share may be overlooked
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,160.30 | 13.70 | -0.15% |
| CAC 40 | 8,280.63 | 21.22 | -0.26% |
| DAX 40 | 25,839.33 | 130.78 | -0.50% |
| Dow JONES (US) | 52,945.00 | 178.12 | 0.34% |
| FTSE 100 | 10,756.45 | 32.83 | -0.30% |
| HKSE | 25,311.21 | 18.52 | -0.07% |
| NASDAQ | 26,179.10 | 79.32 | 0.30% |
| Nikkei 225 | 64,325.64 | 1,889.70 | -2.85% |
| NZX 50 Index | 13,930.57 | 143.67 | 1.04% |
| S&P 500 | 7,660.24 | 28.77 | 0.38% |
| S&P/ASX 200 | 8,978.40 | 1.80 | -0.02% |
| SSE Composite Index | 3,941.39 | 38.50 | -0.97% |